AbbVie (ABBV) Misses Key Phase 3 Survival Goal For Epcoritamab In DLBCL

• AbbVie reported that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in relapsed or refractory diffuse large B cell lymphoma did not meet its primary overall survival endpoint in the US.
• The result affects a key oncology asset that had been part of AbbVie’s plans to expand beyond its established treatments.
• The company is assessing the full data set from the trial to determine next steps for epcoritamab and its broader hematology portfolio.

For investors following AbbVie, ticker NYSE:ABBV, this trial outcome arrives after a period of strong share price performance. The stock recently closed at $259.36 and is up 40.5% over the past year and 167.9% over the past five years, which frames how the market had been viewing the company before this update on epcoritamab.

Looking ahead, attention is likely to focus on how AbbVie positions the rest of its oncology pipeline and existing portfolio in light of this result. Investors may watch for management commentary on any adjustments to development priorities and how the company aims to support future growth alongside its current products.

Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie.

📰 Beyond the headline: 4 risks and 2 things going right for AbbVie that every investor should see.

Investor Checklist: What This Trial Result Means For AbbVie

Quick Assessment

• ⚖️ Price vs Analyst Target: AbbVie trades at US$259.36 versus a consensus target of US$267.79, roughly 3% below where analysts see it on average.
• ✅ Simply Wall St Valuation: Shares are flagged as trading about 43.6% below an estimated fair value, suggesting a wide valuation gap.
• ✅ Recent Momentum: The stock is up 10.4% over the past 30 days, indicating positive recent sentiment despite the trial setback.

There's only one way to know the right time to buy, sell or hold AbbVie. Head to Simply Wall St's company report for the latest analysis of AbbVie's Fair Value.

Key Considerations

• 📊 The failed epcoritamab trial tests confidence in AbbVie’s oncology expansion, so you may want to reassess how much of your thesis relies on this asset.
• 📊 Watch for updated guidance on the hematology pipeline, any write downs, and whether management reaffirms medium term revenue and earnings goals.
• ⚠️ AbbVie already carries high debt and a dividend that is not fully covered by earnings, so additional pipeline disappointments could tighten financial flexibility.

Dig Deeper

For the full picture including more risks and rewards, check out the complete AbbVie analysis. Alternatively, you can check out the community page for AbbVie to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com